N@N

Market Maker Surveillance Report. SGEN, PHMD, CO, GSAT, PTX, BTUUQ, Losing Stocks With Lowest Price Friction For Tuesday, Dece

December 27, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5384 companies with "abnormal" market making, 3620 companies with positive Friction Factors and 2502 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Seattle Genetics, Inc. (NASDAQ:SGEN), PhotoMedex Inc. (NASDAQ:PHMD), China Cord Blood Corporation (NYSE:CO), Globalstar Inc (NYSE:GSAT), Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), Peabody Energy Corp (PINK:BTUUQ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  SGEN    $-9.490   -0.15%    2,017,003    36.72%    2,067,066    37.63%    -50,063      -53     
  PHMD    $-0.380   -0.15%    69,317       25.39%    112,562      41.23%    -43,245      -1,138  
  CO      $-0.970   -0.15%    94,361       30.40%    100,262      32.30%    -5,901       -61     
  GSAT    $-0.240   -0.13%    5,249,124    36.39%    5,960,166    41.32%    -711,042     -29,627 
  PTX     $-0.490   -0.19%    288,072      29.46%    474,290      48.50%    -186,218     -3,800  
  BTUUQ   $-2.030   -0.27%    309,128      33.18%    435,115      46.70%    -125,987     -621    

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows SGEN with a dollar loss Tuesday of $-9.49000 and a Friction Factor of -53 shares. That means that it only took 53 more shares of selling than buying to move SGEN lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

Seattle Genetics, Inc. (NASDAQ:SGEN) - Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS (brentuximab vedotin), an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A, which is in Phase 1b trial for patients with newly diagnosed acute myeloid leukemia (AML); Phase 1/2 trial for patients with relapsed or refractory AML; Phase 1/2 trial for patients with previously untreated myelodysplastic syndrome; and Phase 1 trial for patients with AML. In addition, it is developing SGN-CD19A that is in Phase 2 trials for patients with relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase 1 trial for relapsed or refractory B-cell non-Hodgkin lymphomas, and relapsed or refractory B-cell acute lymphoblastic leukemia; SGN-LIV1A, which is in Phase 1 trial for the treatment of LIV-1-positive metastatic breast cancer; SGN-CD70A that is in Phase 1 trial for the treatment of CD70-positive renal cell carcinoma; SEA-CD40, which is in Phase 1 trial for the treatment of CD40-positive solid tumors; ASG-22ME that is in Phase 1 trial for the treatment of Nectin-4-positive solid tumors, including bladder cancer; and ASG-15ME, which is in Phase 1 trial for the treatment of bladder cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; PSMA Development Company LLC; Takeda Pharmaceutical Company Limited; and Unum Therapeutics, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington..

PhotoMedex Inc. (NASDAQ:PHMD) - PhotoMedex, Inc., a skin health company, provides integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, and consumers in North America, the Asia Pacific, Europe, and South America. The company operates through three segments: Consumer, Physician Recurring, and Professional. It offers products and services that address skin diseases and conditions, including psoriasis, vitiligo, acne, actinic keratosis, photo damage, and unwanted hair. The company also provides various home-use devices under the no no brand name for various indications, such as hair removal, acne treatment, skin rejuvenation, and lower back pain; and a professional product line for acne clearance, skin tightening, psoriasis care, and hair removal to physician clinics and spas. In addition, it offers Kyrobak that uses technology to treat unspecified, lower back pain; NEOVA skin care products for preventing premature skin aging due to UV-induced DNA damage; and Clear Touch, a handheld consumer product for the treatment of nail fungus. Further, the company develops, manufactures, and sells surgical products, including proprietary free-beam and Contact Laser systems for surgery under the PhotoMedex Surgical Products trade name. PhotoMedex, Inc. was founded in 1980 and is headquartered in Horsham, Pennsylvania..

China Cord Blood Corporation (NYSE:CO) - China Cord Blood Corporation, together with its subsidiaries, primarily provides umbilical cord blood storage and ancillary services in the People s Republic of China. The company provides cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as offers matching services. As of March 31, 2016, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company has a strategic collaboration with Cord Blood Registry to share data on cord blood collection, processing, and storage. China Cord Blood Corporation is based in Central, Hong Kong..

Globalstar Inc (NYSE:GSAT) - Globalstar, Inc. provides mobile voice and data communications services through satellite worldwide. The company offers duplex two-way voice and data products, including mobile voice and data satellite communications services and equipment for remote business continuity, recreational, emergency response, and other applications; fixed voice and data satellite communications services and equipment in rural villages, ships, industrial and commercial sites, and residential sites; and satellite data modem services comprising asynchronous and packet data services. It also provides SPOT products, such as SPOT satellite GPS messenger for personal tracking, emergency location, and messaging solutions; SPOT Global phone; and SPOT Trace, an anti-theft and asset tracking device. In addition, the company offers commercial Simplex one-way transmission products to track cargo containers and rail cars, to monitor utility meters, to monitor oil and gas assets, and other applications. Further, it provides engineering services, such as hardware and software designs to develop specific applications; and installation of gateways and antennas. The company primarily serves recreation and personal; government; public safety and disaster relief; oil and gas; maritime and fishing; natural resources, mining, and forestry; construction; utilities; and transportation markets. Globalstar, Inc. distributes its products directly, as well as through independent agents, dealers and resellers, independent gateway operators, and its sales force and e-commerce Website. As of December 31, 2015, it served approximately 688,000 subscribers. The company has a collaboration agreement with Carmanah to design and manufacture solar powered M2M satellite solutions. The company was founded in 2003 and is headquartered in Covington, Louisiana. Globalstar, Inc. is a subsidiary of Thermo Funding II LLC..

Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) - Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products. The company s products comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; and Khedezla, a prescription medication for major depressive disorder. Its products also include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro and Rezira for the relief of cough and nasal congestion; Vituz, a hydrocodone bitartrate and chlorpheniramine maleate combination oral solution for the treatment of cough and allergies associated with the common cold; and OMECLAMOX-PAK, a gastroenterology product. The company sells its products through its sales force and third-party sales organizations, as well as through its subsidiaries. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey..

Peabody Energy Corp (PINK:BTUUQ) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net